| Literature DB >> 34815809 |
Li Yan1, Rebecca A Moriarty1, Kimberly M Stroka1,2,3,4.
Abstract
The blood-brain barrier (BBB) is a semipermeable unit that serves to vascularize the central nervous system (CNS) while tightly regulating the movement of molecules, ions, and cells between the blood and the brain. The BBB precisely controls brain homeostasis and protects the neural tissue from toxins and pathogens. The BBB is coordinated by a tight monolayer of brain microvascular endothelial cells, which is subsequently supported by mural cells, astrocytes, and surrounding neuronal cells that regulate the barrier function with a series of specialized properties. Dysfunction of barrier properties is an important pathological feature in the progression of various neurological diseases. In vitro BBB models recapitulating the physiological and diseased states are important tools to understand the pathological mechanism and to serve as a platform to screen potential drugs. Recent advances in this field have stemmed from the use of pluripotent stem cells (PSCs). Various cell types of the BBB such as brain microvascular endothelial cells (BMECs), pericytes, and astrocytes have been derived from PSCs and synergistically incorporated to model the complex BBB structure in vitro. In this review, we summarize the most recent protocols and techniques for the differentiation of major cell types of the BBB. We also discuss the progress of BBB modeling by using PSC-derived cells and perspectives on how to reproduce more natural BBBs in vitro. © The author(s).Entities:
Keywords: blood-brain barrier; brain microvascular endothelial cells; disease modeling.; neurovascular unit; pluripotent stem cells
Mesh:
Year: 2021 PMID: 34815809 PMCID: PMC8581424 DOI: 10.7150/thno.63195
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1The overview of the components of NVU. BMECs connected by junction proteins intimate contact astrocytes and astrocytes in basement membrane creating a strong barrier. This barrier interacts with other brain cell types such as neurons, microglia, and oligodendrocytes to maintain the brain homeostasis.
Representative studies for hPSC-derived pericytes
| Cell lines | Initial stage | Pericytes specification | Markers | Functional assessment | Reference |
|---|---|---|---|---|---|
| H9.2, I6, C3, KTR13 | Spontaneously differentiation EBs | EBM-2, EC M-19, FBS | CD105, CD90, CD73, CD31, CD146, NG2, and PDGFR positive | Pericytes and EC assembly |
|
| H9, H13, clone 26 hCBiPS aMHCneoPGKhygro+, pCAGGS2, hiPSC-MR31, hESC-H9, hiPSC-BC1 | Early vascular cells 12d | EVC: CIV serum VEGF, SB431542 in EC media | CD73, NG2, PDGFRβ, CD44 positive, VE-cadherin and CD31 negative | Self-organized vascular networks in collagen and HA hydrogels | |
| HESC-NL4, Fib-iPSC BOEC-iPSC, NL-HES4, HES3 (NKX2-5eGFP/w) | CD31- fraction | Activin A, BMP4, CHIR99021, VEGF, SB43152 | PDGFRβ, CD146, NG2, CD73, CD44, CD105 | Vascular Plexus |
|
| ESI-017 | EB | BMP4, FGF2, Activin-A, VEGFA, SB431542 | CD146, CD73, and CD105 positive; CD31, CD34, and CD133 negative | Tube formation assay |
|
| H1, H9-EGFP, IISH2i-BM9 | Mesenchymal progenitors | FGF2, PDGF-BB, SB431542, VEGF, EGF | Capillary Phenotype: NG2+ α-SMAlow/ | Vasculature formation |
|
| BC1, C12-RFP | Mesoderm, early vascular, pericyte maturation | sB431542, VEGF, pericytes medium | PDGFRβ, NG2, CD31, Calponin | Transwell: coculture pericytes with hPSC-derived BMEC-like cells |
|
| AD5, AD6, AD13, AD14, AD20, AD22, AD29, H9 (WA09) and H1 (WA01) | Mesoderm | Mesoderm: MIM, DKK1, pericytes medium | PDGFRβ, NG2, CD13, and CD146 positive | Transwell: coculture pericytes with hPSC-derived BMEC-like cells |
|
| H9, IMR90C4, CS03n2 | Neural crest | E6, CHIR99021, SB431542, bFGF, dorsomorphin, FBS | PDGFRβ, NG2 | Self-assembling with endothelial cells |
|
| H1, H9, DF19-11, 005B23.1, CD3-3, PMBC-3-1, WTC11, WT83, Q83X, M2 | Mesoderm | E8BAC medium: E8, BMP4, Activin-A, and CHIR99021 | CD34, CD31 negative, PDGFRβ, α-SMA, SM22 positive | Angiogenesis assay |
|
Representative studies for hPSC-derived astrocytes
| Cell lines | Initial stage | Astrocyte specification | Markers | Functional assessment | References |
|---|---|---|---|---|---|
| H9, H7, IMR90-4 | Neuroepithelia | RA, FGF8, SHH, CNTF, LIF, FBS | S100β, GFAP | glutamate uptake synaptogenesis |
|
| H9, HUES9 | bFGF, EGF | B27, BMP4, LIF | S100β, GFAP, EAAT1, aquaporin | Oxidative neuronal injury |
|
| WA-09, WA-01, IMR90- | N2, bFGF, FGF, EGF, CNTF, | N2, CNTF | S100β, GFAP | Migratory capacity |
|
| H9, H14, BC1 | B27, bFGF, CNTF, BMP | CNTF, BMP, FBS | GFAP, TUJ1 | Integrate |
|
| N116213, N117322, 409B2, APP1E111, APP1E211, APP1E311, APP2E22, APP2E26, AD3E211, AD8K213 | Cortical neuron: | Repeat passage to a non-coated polystyrene dish | GFAP | Accumulation of Ab oligomers |
|
| 4.2 line, GM003814 unaffected 21.8 line, GM002183; SMA 3.6 | bFGF, EGF, | B27, CNTF | GFAP | Disease phenotypes of SMA |
|
| M337V-1, M337V-2, CTRL-1 iPSC line, CTRL-2 iPSC line | LIF, EGF, bFGF, | B27, CNTF | S100β, GFAP | Astrocyte-neuronal co-culture |
|
| H9, SeV-derived iPSC line and modRNA-derived iPSC line | N2, bFGF, EGF, FGF, CNTF, Noggin, SB431542 | CNTF | A2B5, GFAP |
| |
| HC1, HC2, HC3, MS1, MS2, MS3, MS4, | Noggin, bFGF, SB431542 | bFGF, EGF, LIF, CNTF | S100β, GFAP, GLAST | Disease phenotypes of multiple sclerosis |
|
| WA09, H9, RRID:CVCL_9973,GM1-4, RRID:CVCL_7290 | N2, B27, SB431542, DMH1 | SHH, CHIR99021, CNTF, cyclopamine, prumorphamine, RA, bFGF, BMP4. | Regional markers: S100β, SOX9, GFAP, | Basic membrane properties |
|
Figure 2Strategies of in vitro BBB models. (A) transwell BBB model; (B) BBB spheroid and organoid model; (C) Sandwich BBB model; (D) Cylindrical tubular BBB model; (E) Parallel BBB model; (F) Self-organized BBB model.
Representative studies for hPSC-derived microfluidic BBB-on-chip
| Cell lines | Seed cells | Fluidic channel | Shear stress | Matrix | BBB markers | Function | Time of observation | Reference |
|---|---|---|---|---|---|---|---|---|
| BC1 | UM BMEC-like cells | four rectangular channels with | 4 and 12 dyne/cm2 | Collagen IV, Fibronectin | Occludin | Cell morphology, proliferation, apoptosis, protein gene expression under shear stress | 40 h |
|
| IMR-90-4 | UM-RA BMEC-like cells, Rat primary astrocytes | Neuronal Chamber: 6.5 mm diameter | 0.023-1.8 dyne/cm2 | Collagen IV, Fibronectin | Claudin-5, ZO-1 | TEER: 2000-4000 Ω·cm2 | 10 days |
|
| BC1 | UM-RA BMEC-like cells | Diameter: 150 μm | 0.1, 1 dyne/cm2 | Collagen I | ZO-1, Claudin-5 | TEER: transwell | 3 days |
|
| CS0617iCTR, CS0172 iCTR, CS0188 iCTR, CS81iHD, CS03iCTR, CS03iCTRmut, CS01iMCT8, CS01iMCT8Cor | UM-RA BMEC-like cells, primary pericytes and astrocytes | Brain channel: 1×1 mm | 0.01, 0.5, 2.4,5 dyne/cm2 | Collagen IV, Fibronectin | Occludin | TEER | 10 days |
|
| IMR90-4 | Hypoxia induced UM-RA BMEC-like cells, human primary pericytes, and astrocytes | Brain channel: 2cm long×1mm wide×1mm high | 6 dyne/cm2 | Collagen IV, Fibronectin | ZO-1, Claudin-5, PECAM-1, GLUT--1, Pgp | TEER: 25000 Ω | 2 weeks |
|
| BC1-GFP, C12-RFP | CHIR-RA BMEC-like cells | Diameter: 150 μm | 1 dyne/cm2 | Collagen I, Genipin, Matrigel | ZO-1 | Permeability: Lucifer yellow, 10 kDa dextran | 2 days |
|
| IMR90-4, CC3 | E6 BMEC-like cells, | Diameter: 800 μm | 0.3, 1, 3 dyne/cm2 | Gelatin | Occludin | Permeability: 3 kDa Dextran, Albumin | 21 days |
|
| iPSC-ECs, human primary pericytes, and astrocytes | Self-organized vessels | Not identified | Fibrin gel | ZO-1, Occludin | Permeability: 10 kDa and 40 kDa dextran | 7 days |
|
Representative studies for hPSC-derived BMECs
| Cell lines | Initial stage | BMEC specification | Markers | Functional assessment | Reference |
|---|---|---|---|---|---|
| IMR90-4, | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS | PECAM-1, Claudin-5, GLUT-1, Pgp, VE-cadherin | TEER: ~850 Ω_cm2 |
|
| IMR90-4, DF19-9-11T, H9 | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS, RA | GLUT-1, Claudin-5, Occludin, PECAM-1, VE-cadherin | TEER: ~5000 Ω·cm2 |
|
| IMR90-4 | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS, RA | PECAM-1 | OGD induced |
|
| CS83iCTR33n1, CS14iCTR28n6, | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS, RA | PECAM-1, GLUT-1, Claudin-5, Occludin, ZO-1 | TEER: decreased in HD BMEC-like cells |
|
| DF19-9-11 | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS, RA | Claudin-5, Occludin, ZO-1 | GBS infection assay |
|
| IMR90-4, DF19-9-11T, H9 | Primitive streak-like stage | CHIR99021, bFGF, RA, B27, hESFM, | PECAM-1, ZO-1, VE-cadherin, GLUT-1, Claudin-5, Occludin, BCRP, MRP, Pgp, vWF | TEER: above 3000 Ω·cm2 |
|
| IMR90-4, CD12, SM14, CC3 | Neuroectoderm | E6, hESFM, bFGF, PDS, RA | GLUT-1, Claudin-5, Occludin, PECAM-1, VE-cadherin | TEER: above 2500 Ω·cm2 |
|
| CC3, CD10, HD70-2, and TSP8-15 | Neuroectoderm | E6, hESFM, bFGF, RA, PDS, B27, ITS | PECAM-1, Claudin-5, GLUT-1, VE-cadherin, Occludin | TEER: ~3000 Ω·cm2 |
|
| IMR90-4 | Neural and endothelial co-differentiation | Hypoxia: UM, hESFM, bFGF, PDS, RA | ZO-1, Claudin-5, PECAM-1, GLUT-1, Pgp | TEER: 25000 Ω |
|
| IMR90-4, H1, H6 | Neural and endothelial co-differentiation | UM, hESFM, bFGF, PDS, RA, transduction of | ZO-1, Occludin, PECAM1, CDH5, EPCAM-1 | TEER: ~200 Ω·cm2 |
|
| CC3, CD10, CDH5-2A-eGFP | Neuroectoderm | E6, hESFM, DMEM/F12, neurobasal, bFGF, RA, B27 | GLUT-1, Claudin-5, Occludin, VE-cadherin | TEER |
|
| IMR90-4, iPSC donor 1, 2, and 3. | CD34+CD31+ EC progenitor cells | LaSR, hESFM, B27, bFGF, RA | Claudin-5, Occludin, VE-cadherin, PECAM-1, ZO-1 | TEER |
|